Doan's back-pain relief comparative ad claims challenged by FTC.
This article was originally published in The Tan Sheet
Executive Summary
DOAN'S PILLS BACK PAIN RELIEF COMPARATIVE AD CLAIMS CHALLENGED BY FTC in a complaint against Ciba Self-Medication issued June 26. The Federal Trade Commission is seeking to impose an order requiring Ciba to "cease and desist" from representing, without "competent and reliable supporting evidence," that Doan's pills are "more effective than other over-the-counter analgesic drugs for relieving back pain or any other kind of pain."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning